Phesgo and Tecentriq Performance and Approvals
Phesgo: Conversion rate in early launch countries climbing to 35%
Phesgo reduces administration time & costs
PHESGO®
Phesgo with strong global launch
Roche
Treatment option
Administration and observation schedule*
0.5 1.5 hours
Π
HIV
PIV
2-6 h
1h
1h →
5-8 min
15 - 30 min
Phesgo
Administration time
Ranges driven by differences in loading and maintenance
dose
Global Phesgo conversion rate**
Total time
40%
35%
30%
~2.5-7.5
hours
20%
~20-38 min
10%
0%
90
Q4'20
Q1'21
Q2'21
Q3'21
Q4'21
Q1'22
Q2'22|
Q3'22
Q4'22
Q1'23'
85% of patients preferred Phesgo for Subcutaneous administration over the intravenous formulation of Perjeta and Herceptin
Phesgo conversion rate at 35% in early launch countries, including strong uptake in the US and Germany
• Pivotal Ph I results for Phesgo OBI (on body injector) to enable patient self-administration expected in H2
Source: O'Shaughnessy J, et al. ESMO 2020 (Abstract 165MO); H-Herceptin; P=Perjeta; IV=Intravenous; *Ranges driven by differences in loading and maintenance dose; **Phesgo conversion rate is based on volumes (vials) and
includes all launch countries after the 2nd quarter after the launch (30 countries); Phesgo in collaboration with Halozyme
21View entire presentation